One study from Inano et al. analyzed a relatively small number of patients and indicated the feasibility and efficacy of first-line HDT/ASCT for high-risk patients with DLBCL, in which both CHOP or R-CHOP were used before ASCT [27]. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.